TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31183877
Drug: Hu5F9-G4 (anti-CD47
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hu5F9-G4 (anti-CD47 monoclonal antibody)
Study: 31185735
Drug: Antianginal medication
Normalized name: ANTIANGINALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antianginal medication escalation
Study: 31185735
Drug: Antianginal medication
Normalized name: ANTIANGINALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antianginal medication de-escalation
Study: 31185735
Drug: No change
Approvals — FDA: no, EMA: no, PMDA: no
Description: No change in antianginal medications
Study: 31187454
Drug: Intrathecal VTS-270
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal VTS-270 at doses of 50, 200, 300, or 400 mg per month, escalated to 600 or 1200 mg as tolerated.
Study: 31189673
Drug: Titration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titration of circulating anti-HPV antibodies
Study: 31189673
Drug: Weekly self-samples
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly self-samples for HPV monitoring
Study: 31190006
Drug: Bendamustine 225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine 225 mg/m²
Study: 31190006
Drug: High-dose melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose melphalan (MEL200)
Study: 31190276
Drug: Eribulin 1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin 1.4 mg/m² combined with carboplatin (AUC 5 or 6 mg/mL·min)
Study: 31190276
Drug: Eribulin 1.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin 1.1 mg/m² combined with carboplatin (AUC 5 or 6 mg/mL·min)
Study: 31190298
Drug: Intravenous fosfomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fosfomycin (IV) administered at an average daily dose of 13.7±3.5 g over 12.4±8.6 days, almost exclusively in combination with other antibiotics.
Study: 31191007
Drug: Simotinib, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simotinib, a novel specific EGFR tyrosine kinase inhibitor, dosage and duration not specified.
Study: 31191235
Drug: High-definition transcranial
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-definition transcranial direct current stimulation (HD-tDCS) - 20 daily sessions, 1 mA, 20 min, 4 mm ring radius.
Study: 31191908
Drug: Surveys administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surveys administered in the clinic post-visit to measure CKD-specific health literacy and trust in physician care.
Study: 31192894
Drug: Daily Oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Oral TDF/FTC PrEP
Study: 31193095
Drug: Medical nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical nutrition therapy
Study: 31193580
Drug: Centralized vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centralized vaccine reminder/recall (R/R) via autodialed telephone and mail, up to 3 reminders.
Study: 31193620
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose mebendazole
Study: 31193620
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose mebendazole
Study: 31193674
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g dose of multi-OIT
Study: 31193674
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg dose of multi-OIT
Study: 31193674
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg dose (discontinuation of multi-OIT)
Study: 31194225
Drug: Niraparib 200
Normalized name: niraparib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib 200 mg orally once daily plus Pembrolizumab 200 mg intravenously on day 1 of each 21-day cycle
Study: 31194228
Drug: Niraparib 200
Normalized name: niraparib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib 200 mg orally once daily and Pembrolizumab 200 mg intravenously on day 1 of each 21-day cycle
Study: 31194228
Drug: Niraparib in
Normalized name: Product containing niraparib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib in combination with Pembrolizumab
Study: 31194611
Drug: Nivolumab in
Normalized name: nivolumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab in cohort B (prior therapy)
Study: 31194939
Drug: Daily food
Normalized name: food
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily food choices
Study: 31195062
Drug: Sofosbuvir/velpatasvir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir/velpatasvir (400 mg/100 mg) once daily for 12 weeks
Study: 31196083
Drug: Self-report questionnaires
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-report questionnaires assessing medication adherence (CQR)
Study: 31196083
Drug: Beliefs about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beliefs about Medicines Questionnaire (BMQ)
Study: 31196083
Drug: Satisfaction with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Satisfaction with Information about Medicines Scale (SIMS)
Study: 31198489
Drug: Hormonal skin
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal skin diagnostic testing with intradermal injections of Progesterone, Estradiol, Estrone, and Estriol; followed by serial desensitization injections
Study: 31198489
Drug: Placebo solvent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solvent injections
Study: 31199335
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy (NRT) provided for up to 3 months upon request, along with continuous smoking cessation (SC) counseling and behavioral support.
Study: 31199335
Drug: Safety assessments
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety assessments included adverse events and serious adverse events, body weight, vital signs, spirometry, electrocardiogram, clinical chemistry, hematology and urine analysis safety panel, physical examination, and concomitant medications.
Study: 31199341
Drug: Adjunct treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunct treatment components tailored for YMSM including assertive communication training videos and motivational interviewing focused on assisting with identification and development (MI-AID) before CHTC.
Study: 31199347
Drug: Arousal feedback-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arousal feedback-based exposure therapy
Study: 31201085
Drug: De-escalation of
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De-escalation of TKI treatment to half the standard dose for 12 months, then stopped for a further 24 months.
Study: 31201169
Drug: Daratumumab (DARA)
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab (DARA) 16 mg/kg
Study: 31201169
Drug: Subcutaneous bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous bortezomib (1.3-1.5 mg/m2)
Study: 31204145
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (60-min session, three times a week for three months)
Study: 31204595
Drug: IN.PACT Admiral
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN.PACT Admiral Drug-Coated Balloon
Study: 31205473
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose antivenom
Study: 31205473
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose antivenom
Study: 31205473
Drug: Preantivenom subcutaneous
Normalized name: Viper antivenom
DrugBank: Viper antivenom (DB14114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preantivenom subcutaneous adrenaline (SCAd)
Study: 31205473
Drug: IV adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV adrenaline infusion (IVAI)
Study: 31206074
Drug: 2-year camp-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-year camp-based immersion family treatment for obesity
Study: 31206074
Drug: outpatient family-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: outpatient family-based treatment for obesity
Study: 31207561
Drug: Controlled pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled pharmacotherapy for psychotic depression
Study: 31208944
Drug: Ibrutinib plus
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib plus FCR (Fludarabine, Cyclophosphamide, Rituximab); Ibrutinib 420 mg/day for 7 days, followed by up to six 28-day cycles of FCR.
Study: 31211792
Drug: Killed bivalent
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Killed bivalent (Vibrio cholerae O1 and O139) whole-cell oral cholera vaccine (SHANCHOL; Shantha Biotechnics) - 2 doses, 14 days apart
Study: 31212080
Drug: Azacitidine (AZA)
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine (AZA) administered post-transplant
Study: 31212683
Drug: Educational text
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational text messages (3 messages weekly for 12 weeks)
Study: 31212833
Drug: P28GST administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: P28GST administration
Study: 31212833
Drug: P28GST treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: P28GST treatment in Crohn's disease patients
Study: 31213500
Drug: Binimetinib (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binimetinib (30 mg b.i.d.) and Pexidartinib (400 mg every morning and 200 mg every evening)
Study: 31213778
Drug: Nurse-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-based intervention for improving medication adherence
Study: 31214997
Drug: Trelagliptin 100
Normalized name: Trelagliptin
DrugBank: Trelagliptin (DB15323)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Trelagliptin 100 mg once weekly for 12 weeks
Study: 31214997
Drug: Daily DPP-4
Normalized name: Dipeptidyl peptidase 4 (DPP-4) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily DPP-4 inhibitor for 12 weeks
Study: 31214997
Drug: Daily DPP-4
Normalized name: Dipeptidyl peptidase 4 (DPP-4) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily DPP-4 inhibitor
Study: 31214997
Drug: Trelagliptin and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trelagliptin and daily DPP-4 inhibitors
Study: 31215195
Drug: Fluorescent imaging
Normalized name: Fluorescein
DrugBank: Fluorescein (DB00693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluorescent imaging agent IS-001
Study: 31215264
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin and fondaparinux (Control)
Study: 31216011
Drug: Incretin-based therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incretin-based therapies
Study: 31216011
Drug: Exogenous incretin
Normalized name: Secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exogenous incretin infusions
Study: 31217479
Drug: TSR-011 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSR-011 40 mg every 8 hours (Q8h)
Study: 31217479
Drug: TSR-011 320-
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSR-011 320- and 480-mg Q24h doses
Study: 31217479
Drug: TSR-011 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSR-011 40 mg Q8h
Study: 31217818
Drug: Weekly irinotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly irinotecan at 80 mg/m² in combination with capecitabine-based radiotherapy (50 Gy/25 fractions)
Study: 31217992
Drug: Home-based heart
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based heart failure tool (education, symptom monitoring, diuretic titration)
Study: 31217993
Drug: HART PAD
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: HART PAD panel (clinical variable: history of hypertension; biomarkers: midkine, kidney injury molecule-1, interleukin-23, follicle-stimulating hormone, angiopoietin-1, eotaxin-1)
Study: 31218013
Drug: Accelerated initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Accelerated initiation of renal replacement therapy (RRT) within 12 hours of meeting eligibility criteria
Study: 31218013
Drug: Standard initiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard initiation of renal replacement therapy (RRT) based on clinician judgment or urgent complications
Study: 31219975
Drug: Intensive combined
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive combined chemotherapy (C-CAR-cohort)
Study: 31220258
Drug: Cefoxitin (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (loading dose followed by constant infusion)
Study: 31220258
Drug: Cefoxitin (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (standard dosing regimen)
Study: 31220276
Drug: Subcutaneous (sc)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (sc) prolonged suppressive antibiotic therapy (PSAT) using ertapenem, ceftriaxone, or ceftazidime
Study: 31220276
Drug: Subcutaneous (sc)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (sc) PSAT
Study: 31220349
Drug: Ledipasvir-sofosbuvir (weight-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir-sofosbuvir (weight-based doses: 33.75 mg/150 mg for weights <17 kg or 45 mg/200 mg for weights ≥17 kg) for 12 weeks
Study: 31220400
Drug: Salvage radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salvage radiotherapy (SRT) with pre-SRT PSA level <0.5 ng/mL
Study: 31220400
Drug: Delayed SRT
Normalized name: SRT-1720
DrugBank: SRT-1720 (DB17057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed SRT with PSA level ≥0.5 ng/mL
Study: 31220400
Drug: Early SRT
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early SRT at PSA level <0.5 ng/mL
Study: 31220400
Drug: SRT alone
Normalized name: SRT-1720
DrugBank: SRT-1720 (DB17057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRT alone in patients with PSA level ≥0.5 ng/mL and higher-risk features
Study: 31220623
Drug: Rapid saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid saline infusion
Study: 31220942
Drug: S100a9 neutralizing
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: S100a9 neutralizing antibody administration
Study: 31222720
Drug: G-estimation using
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-estimation using a quadratic approximation approach inspired by iteratively reweighted least squares.
Study: 31222722
Drug: CUSP9-LD (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: CUSP9-LD (low-dose CUSP9) combined with Bcl-2/Bcl-xL inhibitor ABT263
Study: 31222783
Drug: Sofosbuvir plus
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir plus ribavirin for 12 weeks (genotype 2) or 24 weeks (genotype 3); Sofosbuvir dosage: 150 mg for patients aged 3 to <6 years weighing <17 kg, 200 mg for patients aged 3 to <6 years weighing ≥17 kg and all patients aged 6 to <12 years; Ribavirin dosing based on weight (up to 1,400 mg/day, two divided doses).
Study: 31225870
Drug: Human subcutaneous
Normalized name: IgG, human subcutaneous 16 % Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human subcutaneous adipose tissue ATG7 mRNA expression
Study: 31225872
Drug: Dexamethasone (DXM)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DXM) treatment of MCF7 cells
Study: 31225872
Drug: GR antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: GR antagonist RU486
Study: 31226985
Drug: Other approved
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other approved therapies
Study: 31227534
Drug: Highly-interventional spasticity
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Highly-interventional spasticity management (including SDR, ITB, anti-spasticity injections and medications)
Study: 31228101
Drug: Secukinumab 150
Normalized name: secukinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 150 mg no-load
Study: 31228101
Drug: Secukinumab 150
Normalized name: secukinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 150 mg or 150 mg no-load
Study: 31228101
Drug: Secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 300 mg (after dose escalation)
Study: 31228177
Drug: SMART4MD app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: SMART4MD app on a data-enabled computer tablet, used daily at home.
Study: 31228214
Drug: Alcoholic hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcoholic hepatitis patients with ASCA levels ≥34 IU/mL
Study: 31228626
Drug: Durvalumab 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab 10 mg/kg every 2 weeks for 12 months
Study: 31228628
Drug: Ig20Gly infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ig20Gly infusion at rates of ≥60 mL/h/site
Study: 31228628
Drug: Ig20Gly infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ig20Gly infusion
Study: 31228943
Drug: Fluid resuscitation
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid resuscitation with 250 ml albumin 5% boluses repeated as required to restore PPV to < 15% (Fluid non-Responding Status - FnRS)
Study: 31231122
Drug: RRx-001 4
Normalized name: RRx-001
DrugBank: RRx-001 (DB12060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRx-001 4 mg IV on day 1 of each week of a 21-day cycle followed by platinum plus etoposide (80-100 mg IV) at progression
Study: 31231785
Drug: Sunitinib 37.5
Normalized name: sunitinib 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5 mg daily for 12 weeks
Study: 31233323
Drug: Contingency management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingency management (CM) intervention, details on dosage and duration not available.
Study: 31235441
Drug: Ribociclib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib (400 mg per day continuously) plus trastuzumab (6 mg/kg every 3 weeks)
Study: 31235483
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy plus biweekly cetuximab as first-line therapy
Study: 31235630
Drug: High-dose ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ceftriaxone (75 to 100 mg/kg of body weight/day)
Study: 31235775
Drug: Bevacizumab (BVZ)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (BVZ) added to chemotherapy plus trastuzumab (Trast)
Study: 31235775
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus trastuzumab (Trast)
Study: 31235963
Drug: T cell
Normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T cell receptor gene therapy targeting WT1
Study: 31236579
Drug: Toripalimab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab (3 mg/kg d1, Q2W) as monotherapy in cohort 1
Study: 31236579
Drug: Toripalimab (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab (360 mg d1, Q3W) with oxaliplatin (130 mg/m2 qd, d1) and capecitabine (1000 mg/m2 b.i.d., d1-d14, Q3W) in cohort 2
Study: 31236847
Drug: Neoadjuvant nivolumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant nivolumab therapy
Study: 31237206
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy for Leber's hereditary optic neuropathy
Study: 31237839
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of internal facilitator coaching with encouragement of communities of practice (CoPs)
Study: 31238830
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (EVT) with or without intravenous tPA (IVT)
Study: 31238830
Drug: Intravenous tPA
Normalized name: tPA
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tPA (IVT) only
Study: 31239857
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of LAT and MAT
Study: 31240302
Drug: Zolbetuximab (monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolbetuximab (monoclonal antibody) administered intravenously every 2 weeks for five planned infusions; cohorts received doses of 1300 mg/m2, 2600 mg/m2, and 3600 mg/m2.
Study: 31240499
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) monotherapy or combination therapy
Study: 31244718
Drug: Fertility treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fertility treatment (supraphysiological estradiol levels)
Study: 31244760
Drug: CX-8998, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: CX-8998, a selective modulator of the T-Type calcium channel
Study: 31245054
Drug: Subcutaneous abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous abatacept 125 mg weekly for 24 weeks